BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Exagamglogene autotemcel (Casgevy) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Exagamglogene autotemcel (Casgevy)\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05329649-10277@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT053296
 49)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Safety and Efficacy of CTX001 in Pediatric Part
 icipants With Severe Sickle Cell Disease (SCD)\nEstimated primary completi
 on: 6 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exag
 amglogene-autotemcel-casgevy#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05329649
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05477563-10277@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT054775
 63)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Efficacy and Safety of a Single Dose of CTX001 
 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickl
 e Cell Disease\nEstimated primary completion: 9 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0547756
 3
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901933-10277@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 1 readout est. (NCT079019
 33)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 1.\nStudy: Study of 
 CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney 
 Disease\nEstimated primary completion: October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07901933
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05356195-10277@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT053561
 95)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3.\nStudy: Evaluatio
 n of Safety and Efficacy of CTX001 in Pediatric Participants With Transfus
 ion-Dependent β-Thalassemia (TDT)\nEstimated primary completion: 14 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exagamgloge
 ne-autotemcel-casgevy#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05356195
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392255-10277@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 1/2 readout est. (NCT0739
 2255)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 1/2.\nStudy: An Opti
 mised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001
  is Safe and Works for People With Geographic Atrophy (GA)\nEstimated prim
 ary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/exagamglogene-autotemcel-casgevy#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07392255
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208529-10277@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20390930
DTEND;VALUE=DATE:20391001
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT042085
 29)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: A Long-term Follow-up Study in Participants Who Received CTX0
 01\nEstimated primary completion: 30 September 2039. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04208529
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
